Dendritic cell-tumor cell fusion vaccines

Advances in Experimental Medicine and Biology

Volumn 713, Issue , 2011, Pages 177-186

  Lee, Walter T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CELL FUSION; CELL MATURATION; DENDRITIC CELL; HUMAN; HYBRID CELL; IMMUNOSTIMULATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL FUSION; DENDRITIC CELLS; IMMUNOTHERAPY; NEOPLASMS;

EID: 79960968759     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-0763-4_11     Document Type: Article

References (88)

1. Kugler A, Stuhler G, Walden P et al (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6:332-336
2. Editorial (2003) The long road to retraction. Nat Med 9:1093. doi:10.1038/nm0903-1093
3. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252
4. Steinman RM, Pack M, Inaba K (1997) Dendritic cell development and matura-tion. Adv Exp Med Biol 417:1-6
5. Macatonia SE, Hosken NA, Litton M et al (1995) Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 154:5071-5079
6. Gajewski TF, Renauld JC, Van Pel A et al (1995) Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol 154:5637-5648
7. Langenkamp A, Messi M, Lanzavecchia A et al (2000) Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1:311-316
8. Bachmann MF, Kopf M (2002) Balancing protective immunity and immunopa-thology. Curr Opin Immunol 14:413-419
9. Michelsen KS, Aicher A, Mohaupt M et al (2001) The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Pepti-doglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J Biol Chem 276:25680-25686
10. Snijders A, Kalinski P, Hilkens CM et al (1998) High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10:1593-1598
11. Boes M, Cerny J, Massol R et al (2002) T-cell engagement of dendritic cells rap-idly rearranges MHC class II transport. Nature 418:983-988
12. Colledge L, Bennett CL, Reay PA et al (2002) Rapid constitutive generation of a specific peptide-MHC class II complex from intact exogenous protein in immature murine dendritic cells. Eur J Immunol 32:3246-3255
13. Trombetta ES, Ebersold M, Garrett W et al (2003) Activation of lysosomal func-tion during dendritic cell maturation. Science 299:1400-1403
14. Gromme M, Neefjes J (2002) Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol 39:181-202
15. Warren TL, Bhatia SK, Acosta AM et al (2000) APC stimulated by CpG oli-godeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol 165:6244-6251
16. Li Q, Eppolito C, Odunsi K et al (2006) IL-12-programmed long-term CD8+ T cell responses require STAT4. J Immunol 177:7618-7625
17. Valenzuela JO, Hammerbeck CD, Mescher MF (2005) Cutting edge: Bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T cells. J Immunol 174:600-604
18. Thieu VT, Yu Q, Chang HC et al (2008) Signal transducer and activator of tran-scription 4 is required for the transcription factor T-bet to promote T helper 1 cell-fate determination. Immunity 29:679-690
19. Boczkowski D, Nair SK, Snyder D et al (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465-472
20. Fields RC, Shimizu K, Mule JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95:9482-9487
21. Zitvogel L, Mayordomo JI, Tjandrawan T et al (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimula-tion, and T helper cell 1-associated cytokines. J Exp Med 183:87-97
22. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving be-yond current vaccines. Nat Med 10:909-915
23. Shu S, Cohen P (2001) Tumor-dendritic cell fusion technology and immunother-apy strategies. J Immunother 24:99-100
24. Koido S, Hara E, Homma S et al (2009) Cancer vaccine by fusions of dendritic and cancer cells. Clin Dev Immunol 2009:657369
25. Shimizu K, Kuriyama H, Kjaergaard J et al (2004) Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 27:265-272
26. Yasuda T, Kamigaki T, Nakamura T et al (2006) Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Oncol Rep 16:1317-1324
27. Cheong SC, Blangenois I, Franssen JD et al (2006) Generation of cell hybrids via a fusogenic cell line. J Gene Med 8:919-928
28. Phan V, Errington F, Cheong SC et al (2003) A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med 9:1215-1219
29. Lentz BR (1994) Polymer-induced membrane fusion: potential mechanism and relation to cell fusion events. Chem Phys Lipids 73:91-106
30. Lentz BR (2007) PEG as a tool to gain insight into membrane fusion. Eur Biophys J 36:315-326
31. Kohler G, Milstein C (1976) Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 6:511-519
32. Neil GA, Zimmermann U (1993) Electrofusion. Methods Enzymol 220:174-196
33. Burt JP, Pethig R, Gascoyne PR et al (1990) Dielectrophoretic characterisation of Friend murine erythroleukaemic cells as a measure of induced differentiation. Biochim Biophys Acta 1034:93-101
34. Zimmermann U, Vienken J (1982) Electric field-induced cell-to-cell fusion. J Membr Biol 67:165-182
35. Lindner M, Schirrmacher V (2002) Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol ver-sus electro-fusion protocols. Eur J Clin Invest 32: 207-217
36. Orentas RJ, Schauer D, Bin Q et al (2001) Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 213:4-13
37. Weise JB, Hilpert F, Heiser A et al (2004) Electrofusion generates diverse DC-tumour cell hybrids for cancer immunotherapy. Anticancer Res 24:929-934
38. Shu S, Zheng R, Lee WT et al (2007) Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. Crit Rev Immunol 27:463-483
39. Kjaergaard J,Wang LX, Kuriyama H et al (2005) Active immunotherapy for ad-vanced intracranial murine tumors by using dendritic cell-tumor cell fusion vac-cines. J Neurosurg 103:156-164
40. Kjaergaard J, Shimizu K, Shu S (2003) Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 225:65-74
41. Tanaka H, Shimizu K, Hayashi T et al (2002) Therapeutic immune response in-duced by electrofusion of dendritic and tumor cells. Cell Immunol 220:1-12
42. Lee WT, Tamai H, Cohen P et al (2008) Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids. Arch Oto-laryngol Head Neck Surg 134:608-613
43. Kuriyama H, Shimizu K, Lee W et al (2004) Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol (Basel) 116:169-178; discussion 179-186
44. Tanaka Y, Koido S, Ohana M et al (2005) Induction of impaired antitumor im-munity by fusion of MHC class II-deficient dendritic cells with tumor cells. J Immunol 174:1274-1280
45. Bateman AR, Harrington KJ, Kottke T et al (2002) Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 62:6566-6578
46. Cohen PA, Peng L, Plautz GE et al (2000) CD4+ T cells in adoptive immuno-therapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 20:17-56
47. Scott-Taylor TH, Pettengell R, Clarke I et al (2000) Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 1500:265-279
48. Weise JB, Maune S, Gorogh T et al (2004) A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC. Auris Nasus Larynx 31:149-153
49. Avigan D (2004) Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res 10:6347S-6352S
50. Avigan D (2003) Fusions of breast cancer and dendritic cells as a novel cancer vaccine. Clin Breast Cancer 3: S158-163
51. Imura K, Ueda Y, Hayashi T et al (2006) Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique. Int J Oncol 29: 531-539
52. Trefzer U, Herberth G, Wohlan K et al (2005) Tumour-dendritic hybrid cell vac-cination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 23:2367-2373
53. Koido S, Hara E, Homma S et al (2005) Dendritic cells fused with allogeneic co-lorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 11:7891-7900
54. Koido S, Hara E, Torii A et al (2005) Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and me-tastatic colorectal cancer cells. Int J Cancer 117:587-595
55. Jantscheff P, Spagnoli G, Zajac P et al (2002) Cell fusion: an approach to gener-ating constitutively proliferating human tumor antigen-presenting cells. Cancer Immunol Immunother 51:367-375
56. Parkhurst MR, DePan C, Riley JP et al (2003) Hybrids of dendritic cells and tu-mor cells generated by electrofusion simultaneously present immunodominant epi-topes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 170:5317-5325
57. Lee WT, Shimizu K, Kuriyama H et al (2005) Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Otolaryngol Head Neck Surg 132:755-764
58. Hayashi T, Tanaka H, Tanaka J et al (2002) Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 104:14-20
59. Kuriyama H, Watanabe S, Kjaergaard J et al (2006) Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. Cell Immunol 243:30-40
60. Vasir B, Wu Z, Crawford K et al (2008) Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant expo-sure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J Immunol 181:808-821
61. Xia D, Li F, Xiang J (2004) Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother Radiopharm 19:322-330
62. Suzuki T, Fukuhara T, Tanaka M et al (2005) Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor im-munity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 11:58-66
63. Shi M, Su L, Hao S et al (2005) Fusion hybrid of dendritic cells and engineered tumor cells expressing interleukin- 12 induces type 1 immune responses against tumor. Tumori 91:531-538
64. Enomoto Y, Bharti A, Khaleque AA et al (2006) Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells. J Immunol 177:5946-5955
65. McConnell EJ, Pathangey LB, Madsen CS et al (2002) Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model. J Surg Res 107:196-202
66. Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187-207
67. Lee WT, Tan C, Koski G et al (2010) Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids. Head Neck 32:1209-1216
68. Yang JY, Cao DY, Ma LY et al (2010) Dendritic cells fused with allogeneic he-patocellular carcinoma cell line compared with fused autologous tumor cells as hepatocellular carcinoma vaccines. Hepatol Res 40:505-513
69. Lundqvist A, Palmborg A, Bidla G et al (2004) Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses. Med Oncol 21:155-165
70. Zhang Y, Ma B, Zhou Y et al (2007) Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat 105:277-286
71. Cao DY, Yang JY, Yue SQ et al (2009) Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma. Cell Immunol 259:13-20
72. Siders WM, Vergilis KL, Johnson C et al (2003) Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 7:498-505
73. Yu Z, Ma B, Zhou Y et al (2007) Allogeneic Tumor Vaccine Produced by Elec-trofusion between Osteosarcoma Cell Line and Dendritic Cells in the Induction of Antitumor Immunity. Cancer Invest 18:1-7
74. Siders WM, Garron C, Shields J et al (2009) Induction of antitumor immunity by semi-allogeneic and fully allogeneic electrofusion products of tumor cells and dendritic cells. Clin Transl Sci 2:75-79
75. Branham-OćConnor M, Li J, Kotturi HS et al (2010) Fusion induced reversal of dendritic cell maturation: an altered expression of inflammatory chemokine and chemokine receptors in dendritomas. Oncol Rep 23:545-550
76. Garside P, Ingulli E, Merica RR et al (1998) Visualization of specific B and T lymphocyte interactions in the lymph node. Science 281:96-99
77. CahalanMD, Parker I (2005) Close encounters of the first and second kind: T-DC and T-B interactions in the lymph node. Semin Immunol 17:442-451
78. Avigan D, Vasir B, Gong J et al (2004) Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 10:4699-4708
79. Avigan DE, Vasir B, George DJ et al (2007) Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30:749-761
80. Kikuchi T, Akasaki Y, Abe T et al (2004) Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27:452-459
81. Zhou J, Weng D, Zhou F et al (2009) Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol Immunother 58:1587-1597
82. Bedrosian I, Mick R, Xu S et al (2003) Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 21:3826-3835
83. Chi KH, Liu SJ, Li CP et al (2005) Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 28:129-135
84. Kaufman HL, Divgi CR (2005) Optimizing prostate cancer treatment by combin-ing local radiation therapy with systemic vaccination. Clin Cancer Res 11:6757-6762
85. Ding ZC, Blazar BR, Mellor AL et al (2010) Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunc-tional helper phenotype. Blood 115:2397-2406
86. Bauer C, Bauernfeind F, Sterzik A et al (2007) Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut 56:1275-1282
87. Ribas A, Comin-Anduix B, Chmielowski B et al (2009) Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15:6267-6276
88. Ostrand-Rosenberg S (2008) Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18:11-18